SALT LAKE CITY, March 21, 2018 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a specialty pharmaceutical company, announced today
that Dr. Mahesh Patel, Chairman,
President and CEO, will provide a corporate overview at the
17th Annual Needham Healthcare Conference, taking place
March 27th –
28th at the Westin New York Grand Central Hotel in
New York City.
|
Lipocine
Presentation Details
|
|
Date:
|
Wednesday, March
28th
|
|
Time:
|
12:45pm Eastern
Time
|
|
Location:
|
Westin Grand Central
Hotel
|
|
Webcast:
|
http://wsw.com/webcast/needham86/lpcn/
|
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. Lipocine's
clinical development pipeline includes three development programs:
TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug
of testosterone containing testosterone undecanoate, is designed to
help restore normal testosterone levels in hypogonadal men. TLANDO
was well tolerated and met the primary efficacy end-points in Phase
3 testing with twice daily dosing and is currently under FDA
review. LPCN 1111, a novel oral prodrug of testosterone,
originated and is being developed by Lipocine as a next-generation
oral testosterone product with potential for once-daily dosing and
is currently in Phase 2 testing. LPCN 1107 is potentially the
first oral hydroxyprogesterone caproate product candidate indicated
for the prevention of recurrent preterm birth, is currently in
Phase 2 testing and has been granted orphan drug designation by the
FDA. For more information, please visit www.lipocine.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-17th-annual-needham-healthcare-conference-300616031.html
SOURCE Lipocine Inc.